• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Outcomes of therapy with venetoclax combined with a hypomethylating agent in favorable-risk acute myeloid leukemia.

作者信息

Arslan Shukaib, Zhang Jianying, Dhakal Prajwal, Moran Jenna, Naidoo Nuthana, Lombardi Jennifer, Pullarkat Vinod, Stein Anthony S, Marcucci Guido, Yaghmour George, Bhatt Vijaya R, Fathi Amir T, Aldoss Ibrahim

机构信息

Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, California, USA.

Department of Information Sciences, City of Hope Medical Center, Duarte, California, USA.

出版信息

Am J Hematol. 2021 Mar 1;96(3):E59-E63. doi: 10.1002/ajh.26057. Epub 2020 Dec 8.

DOI:10.1002/ajh.26057
PMID:33227142
Abstract
摘要

相似文献

1
Outcomes of therapy with venetoclax combined with a hypomethylating agent in favorable-risk acute myeloid leukemia.维奈托克联合低甲基化药物治疗低危急性髓系白血病的疗效
Am J Hematol. 2021 Mar 1;96(3):E59-E63. doi: 10.1002/ajh.26057. Epub 2020 Dec 8.
2
Hypomethylating agents and venetoclax in acute myeloid leukemia.急性髓系白血病中的去甲基化药物与维奈克拉
Clin Adv Hematol Oncol. 2021 Feb;19(2):82-83.
3
The feasibility of venetoclax and decitabine in therapy-related acute myeloid leukemia with concurrent advanced non-hematological malignancies.维奈托克和地西他滨用于治疗相关急性髓系白血病合并晚期非血液系统恶性肿瘤的可行性。
Leuk Res. 2019 Sep;84:106196. doi: 10.1016/j.leukres.2019.106196. Epub 2019 Jul 30.
4
Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia.维奈克拉与去甲基化药物联合治疗复发/难治性急性髓系白血病的疗效
Haematologica. 2018 Sep;103(9):e404-e407. doi: 10.3324/haematol.2018.188094. Epub 2018 Mar 15.
5
Association of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia.白血病遗传学与复发/难治性急性髓系白血病对维奈托克和去甲基化药物反应的关联
Am J Hematol. 2019 Oct;94(10):E253-E255. doi: 10.1002/ajh.25567. Epub 2019 Jul 10.
6
Venetoclax with decitabine or azacitidine for AML.维奈托克联合地西他滨或阿扎胞苷治疗急性髓系白血病
Lancet Oncol. 2018 Dec;19(12):e672. doi: 10.1016/S1470-2045(18)30824-6. Epub 2018 Nov 1.
7
Decitabine and venetoclax for IDH1/2-mutated acute myeloid leukemia.地西他滨和维奈克拉治疗异柠檬酸脱氢酶1/2突变的急性髓系白血病
Am J Hematol. 2021 May 1;96(5):E154-E157. doi: 10.1002/ajh.26122. Epub 2021 Feb 19.
8
Rebound thrombocytosis is associated with response in AML patients treated with venetoclax and hypomethylating agents.反应性血小板增多症与接受维奈克拉和低甲基化药物治疗的急性髓系白血病（AML）患者的反应相关。
Am J Hematol. 2021 May 1;96(5):E140-E143. doi: 10.1002/ajh.26117. Epub 2021 Feb 18.
9
Venetoclax plus decitabine induced complete remission with molecular response in acute myeloid leukemia relapsed after hematopoietic stem cell transplantation.维奈托克联合地西他滨可诱导造血干细胞移植后复发的急性髓系白血病完全缓解并伴有分子学反应。
Am J Hematol. 2019 Feb;94(2):E48-E50. doi: 10.1002/ajh.25352. Epub 2018 Nov 29.
10
Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: An exposure-response analysis.优化新型老年急性髓系白血病患者联合低强度治疗方案中的维奈托克剂量：暴露反应分析。
Hematol Oncol. 2019 Oct;37(4):464-473. doi: 10.1002/hon.2646. Epub 2019 Aug 2.

引用本文的文献

1
A Century of Hypomethylating Agent: A Remarkable Response to Azacitidine Monotherapy for Relapsed Acute Myeloid Leukemia - A Case Report.一个世纪的低甲基化剂：阿扎胞苷单药治疗复发急性髓系白血病的显著疗效——病例报告
Case Rep Oncol. 2025 May 15;18(1):575-581. doi: 10.1159/000545569. eCollection 2025 Jan-Dec.
2
Venetoclax in combination with hypomethylating agents in newly diagnosed and relapsed acute myeloid leukemia.维奈托克联合低甲基化药物治疗新诊断和复发的急性髓系白血病
Haematologica. 2025 Jul 1;110(7):1639-1643. doi: 10.3324/haematol.2024.286836. Epub 2025 Feb 20.
3
Long-term survival can be achieved in a significant fraction of older patients with core-binding factor acute myeloid leukemia treated with intensive chemotherapy.
相当一部分老年核心结合因子急性髓系白血病患者接受强化化疗后可实现长期生存。
Haematologica. 2025 Mar 1;110(3):608-620. doi: 10.3324/haematol.2024.285448.
4
Reduced dose azacitidine plus venetoclax as maintenance therapy in acute myeloid leukaemia following intensive or low-intensity induction: a single-centre, single-arm, phase 2 trial.强化或低强度诱导后急性髓系白血病患者采用小剂量阿扎胞苷联合维奈托克作为维持治疗的单中心、单臂、2 期临床试验。
Lancet Haematol. 2024 Apr;11(4):e287-e298. doi: 10.1016/S2352-3026(24)00034-6.
5
Biomarkers of Response to Venetoclax Therapy in Acute Myeloid Leukemia. Venetoclax 治疗急性髓系白血病的反应生物标志物。
Int J Mol Sci. 2024 Jan 24;25(3):1421. doi: 10.3390/ijms25031421.
6
Efficacy of venetoclax combined with hypomethylating agents in young, and unfit patients with newly diagnosed core binding factor acute myeloid leukemia.维奈托克联合去甲基化药物治疗新诊断的核心结合因子急性髓系白血病的年轻及不适合强化疗患者的疗效
Blood Cancer J. 2023 Oct 11;13(1):155. doi: 10.1038/s41408-023-00928-1.
7
Prognostic value of European LeukemiaNet 2022 criteria and genomic clusters using machine learning in older adults with acute myeloid leukemia.基于机器学习的欧洲白血病网 2022 标准和基因组聚类在老年急性髓系白血病中的预后价值。
Haematologica. 2024 Apr 1;109(4):1095-1106. doi: 10.3324/haematol.2023.283606.
8
Sporadic and Familial Acute Myeloid Leukemia with CEBPA Mutations.散发性和家族性伴有 CEBPA 突变的急性髓系白血病。
Curr Hematol Malig Rep. 2023 Oct;18(5):121-129. doi: 10.1007/s11899-023-00699-3. Epub 2023 Jun 1.
9
Hypomethylating agent-based therapies in older adults with acute myeloid leukemia - A joint review by the Young International Society of Geriatric Oncology and European Society for Blood and Marrow Transplantation Trainee Committee.基于低甲基化剂的治疗在老年急性髓系白血病中的应用 - 老年肿瘤学的青年国际学会和欧洲血液和骨髓移植协会学员委员会的联合综述。
J Geriatr Oncol. 2023 Apr;14(3):101406. doi: 10.1016/j.jgo.2022.11.005. Epub 2022 Nov 23.
10
Targeted therapy in NPM1-mutated AML: Knowns and unknowns.NPM1 突变型急性髓系白血病的靶向治疗：已知与未知
Front Oncol. 2022 Sep 27;12:972606. doi: 10.3389/fonc.2022.972606. eCollection 2022.